Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501021 | 0.87 | PIK3CD (0.36) | HRH3SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL25725586 | 0.85 | PIK3CD (0.37) | HRH3SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL25075448 | 0.82 | HRH3 (0.38) | HRH3 | |
| SCHEMBL17285622 | 0.81 | HRH3 (0.42) | HRH3SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL102108 | 0.81 | HRH3 (0.41) | HRH3HSD11B1SMN1; SMN2HTR4 | |
| SCHEMBL25075442 | 0.80 | HRH3 (0.39) | HRH3 | |
| SCHEMBL27058941 | 0.79 | HRH3 (0.44) | HRH3SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL23560328 | 0.78 | HRH3 (0.40) | HRH3HSD11B1SMN1; SMN2 | |
| SCHEMBL15032671 | 0.77 | HRH3 (0.41) | HRH3 | |
| SCHEMBL22526530 | 0.76 | HRH3 (0.39) | HRH3HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |